Cite
HARVARD Citation
Robertson, J. et al. (2016). Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 388 (10063), pp. 2997-3005. [Online].